The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delivered two pivotal positive opinions, paving…
Read More
New Study Reveals Oral Semaglutide Outperforms Orforglipron in Weight Loss and Tolerability
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More
Foundayo Demonstrates Efficacy in Sustaining Weight Loss Post-Injectable Incretin Therapy, Presenting a Novel Oral Option
On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
Navigating the Evolving Landscape of Oral Solid Dosage Development: A Framework for Enhanced Efficiency and Commercial Success
The pharmaceutical industry is witnessing a significant evolution in oral solid dosage (OSD) development, driven by an increasing demand for…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Pinnacle Amidst Oral GLP-1 Approval, Yet Wall Street Remains Measured
Indianapolis-based pharmaceutical giant Eli Lilly and Company has achieved a remarkable milestone, surpassing all global pharmaceutical competitors to claim the…
Read More
Eli Lilly Ascends to Pharma’s Top Revenue Spot Amidst Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced.
Eli Lilly and Company, a venerable titan in the pharmaceutical industry, has achieved an unprecedented milestone, claiming the top spot…
Read More
Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating
In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…
Read More
Lilly Ascends to Pharma’s Top Revenue Spot Amidst Landmark Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Eli Lilly and Company has officially claimed the top spot among global pharmaceutical companies by revenue, a monumental achievement underscored…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Zenith with Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Indianapolis, IN – Eli Lilly and Company, a venerable pharmaceutical giant, has officially seized the top position in global pharmaceutical…
Read MoreYOU MAY HAVE MISSED
